Evidence map›Paper›PMID 23783642›Full record

ArticleDalton transactions (Cambridge, England : 2003)2013

Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.

Alvin A Holder, Patrick Taylor, Anthony R Magnusen, Erick T Moffett, Kyle Meyer, Yiling Hong, Stuart E Ramsdale, Michelle Gordon, Javelyn Stubbs, Luke A Seymour and 10 more

Abstract read
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Alvin A HolderDepartment of Chemistry and Biochemistry, The University of Southern Mississippi, 118 College Drive, #5043, Hattiesburg, Mississippi 39406-0001, USA. alvin.holder@usm.edu
Patrick Taylor
Anthony R Magnusen
Erick T Moffett
Kyle Meyer
Yiling Hong
Stuart E Ramsdale
Michelle Gordon
Javelyn Stubbs
Luke A Seymour
Dhiraj Acharya
Ralph T Weber
Paul F Smith
G Charles Dismukes
Ping Ji
Laura Menocal
Fengwei Bai
Jennie L Williams
Donald M Cropek
William L Jarrett
University of Southern Mississippi · USStony Brook University · USRutgers, The State University of New Jersey · USUniversity of Dayton · USBruker (United States) · USUnited States Army Corps of Engineers · US

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI Vijay Rangachari · 2012 to 2026
$60.2M
Phosphosulindac, miRNAs and cancer racial disparityR01CA140487 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI WILLIAMS, JENNIE L · 2010 to 2014
$1.6M
NCI NIH HHS R01 CA140487NCI NIH HHS R01CA140487NIGMS NIH HHS P20 GM103476
6 · The paper itself

Abstract

We report the synthesis and characterisation of mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes, which were used as potential photodynamic therapeutic agents for melanoma cell growth inhibition. The novel complexes, [Ru(pbt)2(phen2DTT)](PF6)2·1.5H2O 1 (where phen2DTT = 1,4-bis(1,10-phenanthrolin-5-ylsulfanyl)butane-2,3-diol and pbt = 2-(2'-pyridyl)benzothiazole) and [Ru(pbt)2(tpphz)](PF6)2·3H2O 2 (where tpphz = tetrapyrido[3,2-a:2',3'-c:3'',2''-h:2''',3'''-j]phenazine) were synthesised and characterised. Compound 1 was reacted with [VO(sal-L-tryp)(H2O)] (where sal-L-tryp = N-salicylidene-L-tryptophanate) to produce [Ru(pbt)2(phen2DTT)VO(sal-L-tryp)](PF6)2·5H2O 4; while [VO(sal-L-tryp)(H2O)] was reacted with compound 2 to produce [Ru(pbt)2(tpphz)VO(sal-L-tryp)](PF6)2·6H2O 3. All complexes were characterised by elemental analysis, HRMS, ESI MS, UV-visible absorption, ESR spectroscopy, and cyclic voltammetry, where appropriate. In vitro cell toxicity studies (with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay) via dark and light reaction conditions were carried out with sodium diaqua-4,4',4'',4''' tetrasulfophthalocyaninecobaltate(II) (Na4[Co(tspc)(H2O)2]), [VO(sal-L-tryp)(phen)]·H2O, and the chloride salts of complexes 3 and 4. Such studies involved A431, human epidermoid carcinoma cells; human amelanotic malignant melanoma cells; and HFF, non-cancerous human skin fibroblast cells. Both chloride salts of complexes 3 and 4 were found to be more toxic to melanoma cells than to non-cancerous fibroblast cells, and preferentially led to apoptosis of the melanoma cells over non-cancerous skin cells. The anti-cancer property of the chloride salts of complexes 3 and 4 was further enhanced when treated cells were exposed to light, while no such effect was observed on non-cancerous skin fibroblast cells. ESR and (51)V NMR spectroscopic studies were also used to assess the stability of the chloride salts of complexes 3 and 4 in aqueous media at pH 7.19. This research illustrates the potential for using mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes to fight skin cancer.

Indexed as

PhotochemotherapyAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorElectrochemical TechniquesHumansMolecular StructureOrganometallic CompoundsPhotosensitizing AgentsRutheniumStructure-Activity RelationshipVanadiumAntineoplastic AgentsOrganometallic CompoundsPhotosensitizing AgentsRutheniumVanadium

Identifiers

PMID23783642
PMCPMC3751419
OpenAlexW1971166425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.